Oncopharmpod

Updates T-DXd (gastric) & SC Dara (AL Amyloidosis)

Informações:

Synopsis

Discussing recent FDA approvals for expanded indications for trastuzumab-deruxtecan for gastric cancer (based on DESTINY-Gastric01) and SC daratumumab for AL amyloidosis. DESTINY-Gastric01: https://www.nejm.org/doi/full/10.1056/NEJMoa2004413